(Q34086952)

English

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients (English)

1 reference

Europe PubMed Central

30 July 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Toni K Choueiri

16

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

30 July 2017

author name string

Mhd Y Al-Marrawi

1

1 reference

Europe PubMed Central

30 July 2017

Brian I Rini

2

1 reference

Europe PubMed Central

30 July 2017

Lauren C Harshman

3

1 reference

Europe PubMed Central

30 July 2017

Georg Bjarnason

4

1 reference

Europe PubMed Central

30 July 2017

Lori Wood

5

1 reference

Europe PubMed Central

30 July 2017

Ulka Vaishampayan

6

1 reference

Europe PubMed Central

30 July 2017

Mary MacKenzie

7

1 reference

Europe PubMed Central

30 July 2017

Jennifer J Knox

8

1 reference

Europe PubMed Central

30 July 2017

Neeraj Agarwal

9

1 reference

Europe PubMed Central

30 July 2017

Hulayel Al-Harbi

10

1 reference

Europe PubMed Central

30 July 2017

Christian Kollmannsberger

11

1 reference

Europe PubMed Central

30 July 2017

Min-Han Tan

12

1 reference

Europe PubMed Central

30 July 2017

Sun Young Rha

13

1 reference

Europe PubMed Central

30 July 2017

Frede N Donskov

14

1 reference

Europe PubMed Central

30 July 2017

Scott North

15

1 reference

Europe PubMed Central

30 July 2017

Daniel Y Heng

17

1 reference

Europe PubMed Central

30 July 2017

International mRCC Database Consortium

18

1 reference

Europe PubMed Central

30 July 2017

publication date

9 January 2013

1 reference

Europe PubMed Central

30 July 2017

Targeted oncology

1 reference

Europe PubMed Central

30 July 2017

8

1 reference

Europe PubMed Central

30 July 2017

3

1 reference

Europe PubMed Central

30 July 2017

203-209

1 reference

Europe PubMed Central

30 July 2017

https://scigraph.springernature.com/pub.10.1007/s11523-012-0252-7

0 references

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Pazopanib for the treatment of renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4144038

5 July 2018

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0252-7

21 January 2018

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0252-7

21 January 2018

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0252-7

21 January 2018

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0252-7

21 January 2018

Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0252-7

21 January 2018

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal c

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0252-7

21 January 2018

Identifiers

10.1007/S11523-012-0252-7

1 reference

Europe PubMed Central

30 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34086952&oldid=1531334771"